Deakin University
Browse

File(s) under permanent embargo

The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR and any relapses occur early

journal contribution
posted on 2008-11-16, 00:00 authored by D Ross, A Grigg, A Schwarer, C Arthur, K Loftus, A Mills, R Filshie, R Columbus, John Reynolds, J Seymour, S Branford, T Hughes
The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in CMR and any relapses occur early

History

Journal

Blood

Volume

112

Issue

11

Season

Abstract # 1102

Pagination

1 - 1

Publisher

American Society of Hematology

Location

Washington, D. C.

ISSN

0006-4971

eISSN

1528-0020

Language

eng

Notes

Alternative source title : Blood (ASH Annual Meeting Abstracts); Chronic Myeloid Leukemia - Therapy Poster I presented at American Society of Hematology. Annual Meeting (50th : 2008 : San Francisco, California) held from 6 - 9 Dec. 2008

Publication classification

C2.1 Other contribution to refereed journal

Usage metrics

    Research Publications

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC